Andrew J. Cowan, MD, from the Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses advances in chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma.
Zofia Piotrowska, MD, a thoracic medical oncologist, explores the challenges of managing patients with EGFR exon 20 insertion mutations in non-small cell lung cancer.
Clinical trialist and physician investigator Vivek Subbiah, MD, discusses advances in targeting RET-dependent cancers.
Paul K. Paik, MD, a medical oncologist specializing in the care of patients with lung cancer at Memorial Sloan Kettering Cancer Center, in New York, discusses targeted therapies to treat patients with NSCLC harboring MET exon 14 skipping mutations.
Hematologic oncologist and clinical researcher Eytan M. Stein, MD, discusses treatment options for patients with IDH1-mutated relapsed or refractory acute myeloid leukemia.
Hematologic oncologist and clinical researcher Doris M. Ponce, MD, discusses strategies to prevent and treat graft-vs-host disease after allogeneic hematopoietic stem cell transplantation.
Advanced prostate cancer is a spectrum of disease states with varying clinical characteristics. Oncologist and clinical researcher Neal D. Shore, MD, FACS, discusses the latest androgen-deprivation therapies for advanced prostate cancer.
Most patients with extensive-stage small cell lung cancer (SCLC) have a poor prognosis. In this interview with oncologist and clinical researcher Millie Das, MD, several specific immunotherapies are discussed as potential first-line standard of care for patients with extensive-stage SCLC.
Enthusiasm for immunotherapy combinations in TNBC remains high, based on signals of efficacy observed in large phase 3 studies.
Igor Astsaturov, MD, PhD, of the Fox Chase Cancer Center in Philadelphia, Pennsylvania, reviewed therapeutic strategies for patients with pancreatic cancer.
